genome analysis

At the PAG conference, researchers said they are sequencing 100 tomato genomes in 100 days using Oxford Nanopore's PromethIon and a pipeline for maximizing SV diversity.

Though the effect of reference bias was inconsistent, the authors of a new study said it highlights the need for tools or approaches to minimize it.

Foresite Capital and F-Prime Capital joined previous investors in this second Series B closing, bringing the total Series B value to £33 million.

Two recent publications suggest that DeepVariant's machine learning is far superior to traditional methods of variant calling, especially with hardware accelerators.

With the three-year grants, the institutions will continue an initiative that is developing tools and technologies for genome biology research.

With an SBIR Phase II grant in hand, Michigan startup Parabricks is adding both speed and AI to variant calling as it eyes a Series A round next year.

The institutions will develop a cloud-based storage and compute infrastructure for unrestricted and controlled-access data and metadata from NHGRI's projects.

In addition to the federal grant, the startup has received $125,000 from a Michigan technology fund to help commercialize its GPU-based analysis platform.

The UK-based maker of clinical genomics interpretation software is moving into the US and China after carefully researching the differences from European markets.

The new hardware expands Garvan's current system so that it can better support large-scale whole-genome and single-cell sequencing initiatives.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.